WallStSmart

Edwards Lifesciences Corp (EW)vsIntelligent Bio Solutions Inc. (INBS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 160979% more annual revenue ($6.30B vs $3.91M). EW leads profitability with a 17.4% profit margin vs -296.8%. EW earns a higher WallStSmart Score of 61/100 (C+).

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 6.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.48

INBS

Hold

38

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 4.0Quality: 6.0
Piotroski: 2/9Altman Z: -14.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+68.8%)

Margin of Safety

+68.8%

Fair Value

$254.22

Current Price

$86.47

$167.75 discount

UndervaluedFair: $254.22Overvalued
INBSSignificantly Overvalued (-23.2%)

Margin of Safety

-23.2%

Fair Value

$4.26

Current Price

$2.44

$1.82 premium

UndervaluedFair: $4.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW4 strengths · Avg: 9.5/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

INBS3 strengths · Avg: 9.7/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
45.5%10/10

Revenue surging 45.5% year-over-year

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.084/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
46.7x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

INBS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.77M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-170.2%2/10

ROE of -170.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : INBS

The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.7x leaves little room for execution misses.

Bear Case : INBS

The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

EW profiles as a growth stock while INBS is a hypergrowth play — different risk/reward profiles.

INBS carries more volatility with a beta of 4.24 — expect wider price swings.

INBS is growing revenue faster at 45.5% — sustainability is the question.

INBS generates stronger free cash flow (-4M), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 38/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Intelligent Bio Solutions Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology firm specializing in the development of advanced diagnostic solutions and biomarker-driven technologies for drug abuse testing and monitoring. The company's innovative approach harnesses state-of-the-art scientific methodologies to deliver rapid and accurate testing options, enabling timely clinical decision-making and enhancing patient outcomes. As the demand for sophisticated diagnostic tools continues to rise, INBS is strategically positioned to lead the transformation of healthcare diagnostics, underscoring its commitment to improving healthcare quality and efficiency.

Want to dig deeper into these stocks?